Impact News +++ Corporate News: Voltabox AG (EQS) +++ VOLTABOX Aktie +7,50%

HERON THERAPEUTICS Aktie

>Aktienkurs

1.1125 EUR (Tradegate)

Ask: 1.129 EUR / 2651 Stück

Bid: 1.096 EUR / 2740 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 8 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>Performance

1 Woche: -5,5%

1 Monat: -35,2%

3 Monate: -36,8%

6 Monate: -34,2%

1 Jahr: -36,9%

laufendes Jahr: -25,7%

>HERON THERAPEUTICS Aktie

Name:

HERON THERAPEUTICS DL-,01

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US4277461020 / A1XB6K

Symbol/ Ticker:

AXD2 (Frankfurt) / HRTX (NASDAQ)

Kürzel:

FRA:AXD2, ETR:AXD2, AXD2:GR, NASDAQ:HRTX

Index:

Webseite:

https://www.herontx.com/

Profil:

Heron Therapeutics Inc. is a biotechnology company..
>Volltext..

Marktkapitalisierung:

169.7 Mio. EUR

Unternehmenswert:

285.17 Mio. EUR

Umsatz:

128.47 Mio. EUR

EBITDA:

3.22 Mio. EUR

Nettogewinn:

-0.8 Mio. EUR

Gewinn je Aktie:

-0.01 EUR

Schulden:

151.68 Mio. EUR

Liquide Mittel:

14.17 Mio. EUR

Operativer Cashflow:

-24.16 Mio. EUR

Bargeldquote:

0.16

Umsatzwachstum:

-0.18%

Gewinnwachstum:

98.24%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

2 Insider kauften innerhalb der letzten 30 Tage Aktien im Wert von 6.230.657 USD.

Suchwörter:

HERON THERAPEUTICS, HERON THERAPEUTIC

Letzte Datenerhebung:

21.08.25

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 153.29 Mio. St.

Frei handelbar: 99.03%

Leerverk. Aktien: 23.18%

Rückkaufquote: -0.65%

Mitarbeiter: 122

Umsatz/Mitarb.: 1.01 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 273.06%

Bewertung:

KGV: -

KGV lG: -

KUV: 1.33

KBV: -

PEG-Ratio: -

EV/EBITDA: 88.47

Rentabilität:

Bruttomarge: 74.61%

Gewinnmarge: -0.62%

Operative Marge: 0.96%

Managementeffizenz:

Gesamtkaprendite: -0.41%

Eigenkaprendite: -

>Peer Group

Es sind 601 Aktien bekannt.

>Chart & Kurs - NASDAQ

>Alle News

15.08.25 - 13:48	Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value (PR Newswire)
	CARY, N.C., Aug. 15, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that its Board of Directors (the "Board") has adopted a Section 382 rights plan (the "Rights Plan") designed to protect......

13.08.25 - 04:02	Insiderhandel: Insider kauft Aktien von Heron Therapeuti im Wert von 3580838 USD (Insiderkauf)
	Rubric Capital Management Lp - Zehn-Prozent-Eigentümer - Tag der Transaktion: 2025-08-08...

13.08.25 - 00:01	Insiderhandel: Aufsichtsrat kauft Aktien von Heron Therapeuti im Wert von 2649819 USD (Insiderkauf)
	Morgan, Adam - Aufsichtsrat - Tag der Transaktion: 2025-08-08...

08.08.25 - 21:48	Heron Therapeutics raises adjusted EBITDA guidance to $9M-$13M for 2025 amid commercial restructuring and ZYNRELEF J-code milestone (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

08.08.25 - 16:45	Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
	Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers....

08.08.25 - 14:45	Heron Therapeutics announces capital restructuring to support growth (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

08.08.25 - 13:54	Heron Therapeutics GAAP EPS of -$0.02 misses by $0.01, revenue of $37.2M misses by $0.88M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

08.08.25 - 13:48	Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress (PR Newswire)
	Generated Q2 2025 Net Revenue of $37.2 million and year-to-date revenue of $76.1 million; reaffirmed 2025 Net Revenue Guidance of $153 million - $163 million Delivered record year-to-date 2025 Adjusted EBITDA of $7.9 million, raised full-year 2025 Adjusted EBITDA Guidance from $4.0......

08.08.25 - 13:48	Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile (PR Newswire)
	CARY, N.C., Aug. 8, 2025 Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the completion of a comprehensive capital restructuring designed to enhance the Company's financial flexibility, reduce total debt, and......

08.08.25 - 12:03	Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025 (PR Newswire)
	CARY, N.C., Aug. 8, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that it has rescheduled its release of second quarter 2025 financial results and subsequent conference call. The Company......

29.07.25 - 03:45	Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025 (PR Newswire)
	CARY, N.C., July 28, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, August 11, 2025, at 4:30 p.m. ET to report......

06.05.25 - 16:30	Compared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key Metrics (Zacks)
	While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values....

06.05.25 - 13:54	Heron Therapeutics GAAP EPS of $0.01 beats by $0.02, revenue of $38.9M beats by $1.48M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.05.25 - 13:48	Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
	Generated Q1 2025 Net Revenue of $38.9 million Delivered record Q1 2025 Adjusted EBITDA of $6.2 million Reached settlement with Mylan Pharmaceuticals, Inc., regarding the parties' CINVANTI® and APONVIE® patent litigations, including an agreed market entry date of June 1, 2032 Adjusted......

06.05.25 - 13:33	Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations (PR Newswire)
	— Company Grants Mylan a License to Market Generic CINVANTI® and APONVIE® Beginning in June 2032 — CARY, N.C., May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company entered......

05.05.25 - 17:00	Heron Therapeutics Q1 2025 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

29.04.25 - 17:30	Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
	Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

29.04.25 - 00:57	Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer (PR Newswire)
	CARY, N.C., April 28, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the appointment of Mark Hensley as Chief Operating Officer. Mr. Hensley has more than fifteen years of experience in a......

22.04.25 - 22:07	Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025 (PR Newswire)
	CARY, N.C., April 22, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, May 6, 2025, at 8:00 a.m. ET to report first......

27.02.25 - 16:45	Heron Therapeutics (HRTX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
	Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Nur übereilt bestimmt die Neigung sich. - Johann Wolfgang von Goethe

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram